Oxford Biodynamics

Oxford BioDynamics (OBD) is a health-care service company with a proprietary biomarker discovery platform, EpiSwitch, based on the latest advances in the mechanisms of gene expression, non-coding RNA and epigenetics. The technology allows: 1. Screening; early detection and monitoring of major diseases associated with aberrant gene expression, i.e. Cancer, neurodegenerative conditions, such as Alzheimer’s disease, and inflammatory conditions. 2. Early detection of aberrant expression in a very low copy number of abnormal cells, literally “finding a needle in a hay stack” at the early stage of the disease EpiSwitch способна определять 2 типа маркеров: Disease-related biomarkers (diagnostic biomarker and prognostic biomarker) и Drug-related biomarkers.

Main

Formation of Oxford BioDynamics PTE Limited in Singapore

03/08/2007

Formation of Oxford BioDynamics Limited in UK

04/01/2007

Oxford BioDynamics, funded by the Wellcome Trust, Cancer Research UK, the Medical Research Council, EP Abrahams Fund and Exeter College — that has licensed the technology and holds the patents on this research

Создание Oxford BioDynamics Reference лаборатории

01/01/2008

Formation Oxford BioDynamics Australia Pty Limited

02/01/2009

Formation of Oxford BioDynamics Hepa Pte Limited

03/01/2009

In Singapore

New Oxford BioDynamics reference laboratory opens

02/01/2010

Fundraising

Oxford BioDynamics raises $4 million

04/01/2009

Wellcome Trust

$3.2M Rights issue completed by Artradis Testudo Fund and Cubana Investment Ltd

11/01/2011

Artradis Testudo is an Asian hedge fund (located in Singapore) lead by Stephen Diggle. (it's now a part of Vulpes Investment Management).

On 31 January 2012, Cubana Investments Limited ("Cubana") was acquired by Vulpes Life Sciences Fund ("Vulpes"). As a consequence, on 9 March 2012 Cubana's interest in the ordinary shares of the Company were transferred to Vulpes.
So now Vulpes has an interest in 131,950,000 ordinary shares of 1 pence each representing 13.96 per cent of the issues ordinary share capital in Oxford BioMedica

Publications

Публикация Акуличева в журнале Nature

02/07/2007

"Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript"
http://www.nature.com/nature/journal/v445/n7128/full/nature05519.html

Alternative promoters within the same gene are a general phenomenon in gene expression1, 2. Mechanisms of their selective regulation vary from one gene to another and are still poorly understood. Here we show that in quiescent cells the mechanism of transcriptional repression of the major promoter of the gene encoding dihydrofolate reductase depends on a non-coding transcript initiated from the upstream minor promoter and involves both the direct interaction of the RNA and promoter-specific interference. The specificity and efficiency of repression is ensured by the formation of a stable complex between non-coding RNA and the major promoter, direct interaction of the non-coding RNA with the general transcription factor IIB and dissociation of the preinitiation complex from the major promoter. By using in vivo and in vitro assays such as inducible and reconstituted transcription, RNA bandshifts, RNA interference, chromatin immunoprecipitation and RNA immunoprecipitation, we show that the regulatory transcript produced from the minor promoter has a critical function in an epigenetic mechanism of promoter-specific transcriptional repression.

Jane Mellor publication in Genes and Development

07/15/2010

"Transcription: from regulatory ncRNA to incongruent redundancy"
Transcription is such a fundamental process and has been studied by so many for so long that skeptics might ask what more there is to learn. Those who attended the meeting summarized here on the dynamics of eukaryotic transcription during development were not disappointed. Studying the transcription of genes in stem cells during early development and in model organisms has illuminated mechanisms for transcriptional control that would have been hard to accept even 5 years ago, and consistently challenges the textbook view of transcriptional regulation.

http://genesdev.cshlp.org/content/24/14/1449.full

Professor Jane Mellor publishes article on Epigenetics in The Biochemist

10/01/2010

In Biochemist VOLUME 32 NO 5 October 2010 two articles by Jane Mellor presented

  1. Introduction:
    http://www.biochemist.org/bio/default.htm?VOL=32&ISSUE=5

  2. Epigenetics and aging
    Aging is the accumulation of changes in an organism over time that leads to reduced viability. Studies in model organisms indicate that aging is genetically determined and that alterations to specific genes can extend or shorten lifespan. Some organisms exhibit negligible aging with no loss of metabolic functions or fertility over time, despite a high metabolic rate, raising the question as to why and how some organisms age and die. A number of theories of aging have been proposed, including telomere shortening, wear and tear (somatic mutations, error accumulation, loss of protein function, etc.), autoimmune disease and reduced mitochondrial function leading to oxidative stress and damage to DNA and proteins.
    http://www.biochemist.org/bio/default.htm?VOL=32&ISSUE=5

Jane Mellor publishes article on Epigenetics and Longevity in Phenotype Magazine

11/01/2011

International Immunopharmacology publication together with Siamon Gordon

01/01/2014

"Formation of distinct chromatin conformation signatures epigenetically regulate macrophage activation"
http://www.ncbi.nlm.nih.gov/pubmed/24211766

Microbial-lipopolysacharide (LPS), interleukin 4 (IL-4) and interferon gamma (IFN-γ) polarise macrophages into "innate", "alternative" and "classical", activation states by selective gene regulation. Expression of MARCO, CD200, CD200R1 (innate), MRC1 (alternative) and H2-Eb1 (classical) selectively marks these distinct activation states. Epigenetic events drive such activation upon stimuli and here we study one such mechanism, chromatin conformation signatures implicated in long-range chromatin interactions that regulate transcriptional switch and gene expression. The EpiSwitch™ technology was used to identify and analyse potential markers bordering such conformational signatures for these genes and juxtaposition of markers was compared between resting and activated macrophages. LPS, IL-4 and IFN-γ selectively altered chromatin conformations of their responsive genes in wild type, but not in MyD88(-/-), IL-4R(-/-) and IFN-γR(-/-) macrophages. In addition, two distinct conformations were observed in CD200R1 after LPS and IFN-γ stimulation. In summary, signal-specific alterations in chromatin conformation provide biomarkers that identify and determine distinct gene expression programmes during macrophage activation.

Patents

Patent application filled (PCT/GB2207/000564)

02/17/2006

DNA Conformation (17.02.2006 - Priority date)
Countries of patent application: Australia, China, Canada, Europe, World, USA, Japan, HK, UK, New Zealand, South Africa, Norway, Danmark, Spain)
CLAIMS
A method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.

http://worldwide.espacenet.com/publicationDetails/inpadocPatentFamily?CC=ZA&NR=200807948A&KC=A&FT=D&ND=8&date=20091125&DB=EPODOC&locale=en_EP

OBD patent is published in Canada

08/23/2007

DNA CONFORMATION (LOOP STRUCTURES) IN NORMAL AND ABNORMAL GENE EXPRESSION (CA2642331 A1)
CLAIMS
Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.

http://worldwide.espacenet.com/publicationDetails/biblio?CC=CA&NR=2642331A1&KC=A1&FT=D&ND=7&date=20070823&DB=EPODOC&locale=en_EP

Oxford BioDynamics patent is published in South Africa

11/25/2009

DNA Conformation (loop structures) in normal and abnormal gene expression (ZA200807948 A)
CLAIMS
Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=13&ND=7&adjacent=true&locale=en_EP&FT=D&date=20091125&CC=ZA&NR=200807948A&KC=A

Oxford BioDynamics patent is published in New Zealand

07/29/2011

DNA Conformation (loop structures) in normal and abnormal gene expression
CLAIMS
Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.

http://worldwide.espacenet.com/publicationDetails/biblio?CC=NZ&NR=571201A&KC=A&FT=D&ND=7&date=20110729&DB=EPODOC&locale=en_EP

Oxford BioDynamics patent is granted in Europe

08/10/2011

DNA CONFORMATION (LOOP STRUCTURES) IN NORMAL AND ABNORMAL GENE EXPRESSION
CLAIMS
Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.

http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=1991697B1&KC=B1&FT=D&ND=4&date=20110810&DB=EPODOC&locale=en_EP

Oxford BioDynamics patent is granted in Singapore

10/01/2011

OBD patent granted in Australia

04/10/2012

DNA conformation (loop structures) in normal and abnormal gene expression
CLAIMS
Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.

http://worldwide.espacenet.com/publicationDetails/biblio?CC=AU&NR=2007216315B2&KC=B2&FT=D&ND=5&date=20121004&DB=EPODOC&locale=en_EP

OBD patent on EpiSwitch™ biomarker technology is granted in South Africa

08/01/2012

OBD patent on EpiSwitch™ biomarker technology is granted in Singapore

09/01/2012

OBD patent is granted in the UK

02/05/2013

Methods of diagnosis (GB2473392 B)
CLAIMS
A method of monitoring epigenetic changes in conditional long range chromosomal interactions at least 5 one chromosomal locus where different conformations of long range interactions are associated with a change in the level of expression of one or more genes or a change in one or more gene products associated with a condition selected from amongst cancer, cardiovascular disorders, 10 inflammatory conditions, including autoimmune disorders and inflammatory responses to infectious diseases, and inherited genetic disorders modulated by epigenetic mechanisms, said method comprising the steps of:-

(i) in vitro crosslinking of said long range chromosomal 15 interactions present at the at least one chromosomal CY) locus;
(ii) isolating the cross linked DNA from said chromosomal 7-- locus;
(iii) subjecting said cross linked DNA to restriction CX) 20 digestion with an enzyme that cuts at least once within CV the at least one chromosomal locus;
(iv) ligating said cross linked cleaved DNA ends to form DNA loops;
(v) identifying the presence of said DNA loops;
wherein the presence of DNA loops indicates the presence of a specific long range chromosomal interaction and wherein the long range chromosomal interactions are not long range interactions between genes and their regulatory elements.

http://www.ipo.gov.uk/p-ipsum/Case/PublicationNumber/GB2473392

OBD is granted Japanese patent

08/23/2013

DNA CONFORMATION (JP5345857 B2)
CLAIMS
Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.

http://worldwide.espacenet.com/publicationDetails/biblio?CC=JP&NR=5345857B2&KC=B2&FT=D&ND=7&date=20131120&DB=EPODOC&locale=en_EP

OBD is granted Chinese patent

10/30/2013

DNA conformation (loop structures) in normal and abnormal gene expression (CN101384734 B)

http://worldwide.espacenet.com/publicationDetails/biblio?CC=CN&NR=101384734B&KC=B&FT=D&ND=6&date=20131030&DB=EPODOC&locale=en_EP

OBD is granted Singaporean patent on its EpiSwitch™ biomarker technology

02/01/2014

Validation

Validation trial for non-invasive breast cancer screening test results

08/01/2009

Completion pilot study on Melanoma and Hepatocellular carcinoma

07/01/2010

Oxford BioDynamics granted UK Human Tissue Authority licence

08/01/2010

OBD announces completion results for the EpiSwitc Breast Cancer test

09/01/2010

Oxford BioDynamics announces completion of the results of the EpiSwitch™ Breast Cancer test on a cohort of 236 samples spanning different grade of cancer, tumour size, lymph node involvement, hormone receptor and HER2 status. The test is based on the platform technology developed on the backdrop of high standards set in ISO 13485:2003, ISO 9001:2008 and FDA 21 CFR Part 820 requirements. The results of the EpiSwitchTM test for diagnosing women with breast cancer show the upper 95% confidence interval of specificity and sensitivity are 98% and 93% respectively

EpiSwitc can differentiate least from more aggressive prostate cancers

10/01/2010

Oxford BioDynamics has completed a test development using the EpiSwitch™ technology, to differentiate the least aggressive cases of prostate cancer from those that are more aggressive. Least aggressive tumours are categorized as Gleason score 4-6 and either Stage I/II or from patients older than 65, whilst more aggressive cases are Gleason grade 7 and above, and either Stage III+ or less than 65 years old. The test can accurately identify the two groups, providing essential information for physicians to determine whether patients require observation or intervention

Melanoma clinical trial completed

06/01/2011

OBD Prostate Cancer Clinical Trial Completed

10/01/2011

OBD presents its breast cancer, prostate and melanoma test results

01/01/2012

at SingHealth, National Cancer Centre, Singapore

EpiSwitch Alzheimer’s pilot study brings hope for early diagnosis/intervention

03/01/2012

Currently, $183 billion is spent yearly on Alzheimer’s associated costs.

A pilot study was set up to detect the presence of blood biomarkers for systemic epigenetic changes utilising the EpiSwitch™ platform technology. The EpiSwitch™ technology identified the presence of valid biomarkers in key signature genes associated with Alzheimer’s disease, including amyloid precursor protein (APP), apolipoprotein E (APOE) and phosphatidylinositol-binding clathrin assembly protein (PICALM)

The OBD EpiSwitch™ pilot study for Parkinson’s disease completed successfully

03/02/2012

OBD has evaluated the epigenetic read-outs on the loci of the genetic, epigenetic, and protein markers that had been previously identified and independently linked to Parkinson’s disease using the EpiSwitch™ platform technology. Biomarkers suitable for differentiation between PD patients and controls were identified including biomarkers in the loci highly sensitive microtubule-associated protein tau (MAPT), α-synuclein (SNCA) and serine/arginine repetitive matrix 2 (SRRM2). This led to a complete and accurate discrimination between the two groups and shows the utility of this test for further development of a PD diagnostic.

OBD identifies biomarkers for Nasopharyngeal carcinoma

03/03/2012

OBD announces the completion of the pilot study and discovery of EpiSwitch™ biomarkers for NPC.

NPC produces few symptoms early in its course, with the result that most cases are quite advanced when detected. With this in mind, OBD carried out a pilot study on blood samples from Filipino and Singaporean populations with NPC using its EpiSwitch™ technology. Biomarkers from three loci – DLC1, DLEC-1, and RASSF1A showed particularly promising results, differentiating samples from NPC patients and controls, and will be utilised in the final design of the diagnostic test.

OBD completes melanoma clinical meta-trial

07/01/2012

Annual Meeting of Japanese Association of Breast Cancer Screening, Okinawa

11/10/2012

In a prospective study EpiSwitch™ technology identifies a patient who develops breast cancer two years ahead of confirmation.

At the Annual Meeting of the Japanese Association of Breast Cancer Screening, Dr Nomizu presented the results of the EpiSwitchTM analysis, conducted by OBD in collaboration with Otsuka Pharmaceutical Co. Limited. A prospective study has been conducted on the patient, who was diagnosed as healthy by both mammography and ultrasonic examination, but was identified with deregulation, symptomatic of breast cancer, by the EpiSwitchTM technology. Observations carried out over a two year period confirmed that the patient had developed stage 1 breast cancer, with a tumour size of 15 mm.

A collaboration between Oxford BioDynamics and Professor Siamon Gordon (Oxford)

11/01/2013

A collaboration between Oxford BioDynamics and Professor Siamon Gordon (Oxford University), has utilised EpiSwitch™ technology for successful identification of regulatory chromosome conformation signatures as epigenetic biomarkers for innate, alternative and classical activation states in macrophages stimulated with LPS, IL-4 and IFN-γ.

This collaboration led to publication "Formation of distinct chromatin conformation signatures epigenetically regulate macrophage activation" in International Immunopharmacology on Jan 2014
http://www.ncbi.nlm.nih.gov/pubmed/24211766

Collaboration

Initial agreement on a feasibility study conducted by Oxford University and OBD

09/01/2007

Extension of the feasibility study between Oxford University and OBD

05/01/2008

Extension feasibility study Oxford University and Oxford BioDynamics

09/01/2008

Collaboration Agreement signed with CERBM and IGBMC, France

10/01/2008

Заключение Collaboration Agreement с Centre Européen de Recherche en Biologie et en Médecine (CERBM) and the Institute de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), France

Oxford BioDynamics Cardiovascular Pte set up with The Arizona Heart Institute

10/01/2008

Collaboration agreement with Ludwig Institute for Cancer Research

12/01/2008

Extension feasibility study Oxford University and Oxford BioDynamics

03/01/2009

License agreement signed with Chronos Therapeutics Limited

04/01/2009

Chronos на откуп отдали возрастозависимые заболевания (such as muscular and bone degenerative diseases and rarer neurodegenerative diseases), чтобы самим сосредоточиться на раке

Collaboration agreement on Oncology

07/01/2009

Agreement signed with Queen Mary and Westfield College, Centre for Medical Oncology, Institute of Cancer, Barts and the London School of Medicine

Extension feasibility study Oxford University and Oxford BioDynamics

09/01/2009

OBD signs development agreement with pharmaceutical company in Asia

06/01/2010

Oxford BioDynamics signs development agreement with Singapore Health

11/01/2010

Development agreement signed with Super Religare Laboratory Ltd., India

04/01/2011

Signing agreement with USA diagnostic company on Alzheimer’s and Parkinson’s

12/01/2011

One of the major Japan companies wheather Sysmex or Arkray

OBD signs Research and Development agreement with diagnostic company in Japan

12/01/2011

OBD signs an extension of its Collaboration Agreement with a Japanese Pharma

05/02/2012

OBD licences EpiSwitch to Epitech International Pte for Nasopharyngeal carcinoma

06/01/2012

in Singapore

OBD signs Development and Licence Agreement with EpiLIVER Pte Ltd

10/01/2012

in Singapore for Hepatocellular carcinoma

OBD announces signature of a Development Agreement with Janssen R&D

03/01/2013

OBD and major US Pharma announce agreement to differentiate lymphoma subgroups

03/02/2013

Oxford BioDynamics Limited has entered into a Technology and Evaluation Agreement with a second major US Pharmaceutical Company to identify EpiSwitchTM signatures using their EpiSwitchTM Biomarker discovery platform in order to differentiate Diffuse Large B-cell Lymphoma (DLBCL) prognostic subgroups.

OBD signs extension of its Collaboration Agreement with Japanese Pharma

05/02/2013

Oxford Biodynamics signs an extension of its Collaboration Agreement with a major Japanese Pharmaceutical Company under which Oxford Biodynamics Pte Limited, a wholly owned subsidiary of Oxford Biodynamics based in Singapore, to conduct an extended non-invasive test for breast cancer using Japanese samples.

Signing Collaboration agreement with Genome Institute of Singapore (GIS)

05/10/2013

The Genome Institute of Singapore and Oxford Biodynamics Pte have signed a collaboration agreement to jointly develop the EpiSwitchTM technology that can discover the epigenetic signature of stem cells and cell lines.

GIS and OBD, a wholly owned subsidiary of Oxford Biodynamics Limited, have signed a Collaboration Agreement to jointly develop the EpiSwitchTM technology to create a focused EpiSwitchTM epigenetic signature to compare IPSCS, ESCS and Progenitor cell lines.

The new collaboration is an important advancement for current stem technology, as the control of the quality of epigenetic differentiation of stem cells remains one of the most important problems. In their first and immediate application EpiSwitchTM biomarkers will provide a quick and efficient tool to monitor the quality and safety of IPSCs.

OBD signs a major contract with the University of Glasgow

06/01/2013

Agreement with Norfolk and Norwich University Hospitals NHS Foundation Trust

06/02/2013

To utilise its EpiSwitch™ platform technology as part of the Norfolk diabetes prevention study.

OBD and major US Pharma sign agreement on Alzheimer's

12/01/2013

OBD and major US Pharma sign agreement to differentiate Alzheimer’s disease (AD) patients from other cognitive impaired patients.

OBD will identify epigenetic changes based on chromosome conformation signatures that will be able to identify Alzheimer’s disease (AD) patients from whole blood using OBD’s EpiSwitch™ Discovery Platform.

OBD and major US Pharma on Lymphoma

01/01/2014

OBD and major US Pharma sign agreement to develop epigenetic knowledge and biomarkers to be used in the development of treatments for Lymphoma.

Resolution of the mechanisms that lead to the formation of lymphoma using the EpiSwitch Discovery Platform should lead to defined treatments for lymphoma.

OBD and European Pharma sign agreement to identify Non-genotoxic carcinogenesis

01/02/2014

OBD and major European Pharma sign agreement to identify regulatory events underlying the carcinogenic process induced by Non-genotoxic carcinogenesis (NGC).

OBD will use their EpiSwitch™ Discovery Platform to resolve epigenetic knowledge around the carcinogenic process induced by Non-genotoxic carcinogenesis (NGC). The data will be integrated with transcriptional profiling data to mechanistically and functionally characterize this process and develop a new class of potential NGC biomarkers.

OBD signs Breast Cancer screening development licence for South East Asia

01/10/2014

Nova Satra BioDynamics has inked an exclusive licensing agreement with UK-based developer of molecular diagnostic tests, Oxford BioDynamics Limited to supply a ground-breaking, non-invasive Breast cancer molecular diagnostic test in the ASEAN region.

The agreement allows for Nova Satra to market and distribute EpiSwitch.

OBD and US Pharma sign agreement on acute myeloid leukemia

01/11/2014

OBD and major US Pharma sign agreement to develop epigenetic knowledge and biomarkers to be used in the development of co-therapies for the treatment of acute myeloid leukemia (AML)

Appointments

Christian Hoyer Millar becomes Managing Director

06/01/2007

Software Assignment from Dr Aroul Ramadass to Oxford BioDynamics

06/02/2007

Ramadass has developed the key pattern recognition software supporting Oxford BioDynamics’ research.

Now he is leading the reference lab facility

Dr Alexandre Akoulitchev becomes Chief Scientific Officer

01/01/2008

Начало OBD положил Александр Акуличев (в Оксфорд попал из московского Физтеха) в William Dunn School of Pathology (что-то вроде его собственной исследовательской лаборатории в Оксфорде), который и собрал всю команду, распространившуюся в дальнейшем на Oxford Biodynamics, а потом на Chronos и Sibelius.

The real significance of their work, published in the scientific journal Nature, lies in finding that the body’s cells recognise regulatory markers produced by ‘junk’ DNA that determine which genes are switched on, when.

By understanding how to identify these markers, scientists could develop tools to detect not only genetic predisposition to cancer, diabetes and heart disease but also very early signs of infectious diseases such as HIV and tuberculosis.

Professor Karol Sikora appointed chairman Oxford BioDynamics Advisory Board

06/01/2008

Mrs Karen Koh becomes Director of Asia

01/01/2010

Dr Ewan Hunter joins OBD as Business Development Director

04/01/2012

Events

Presentation at 22 International Congress in USA

02/09/2009

organised by The Arizona Heart Institute and International Congress Foundation

Pesenting at Next Generation Sequencing for Research and Clinical Genomics Conf

09/24/2012

Basel, Switzerland (September 24-25)

OBD presented a Next Generation Sequencing (NGS) extension of its EpiSwitchTM technology platform. This technological innovation offers an unbiased discovery of EpiSwitchTM biomarkers. The new approach has been validated for melanoma and was supported by the latest results from OBD for the development and cross-validation of the OBD melanoma test.

This novel approach offers an unprecedented scope for the identification and classification of biomarkers for the stratification of the most challenging clinical conditions, while retaining the unique utility of the EpiSwitchTM read-out.

The data was presented within the Epigenetic Session in a talk entitled “Chromatin Loops, Epigenetics & NGS: Data Driving Biomarkers” by the Company CSO, Dr Alexandre Akoulitchev

Professor Jane Mellor gives a talk at the Cold Spring Harbour Lab

08/27/2013

Prof Mellor presented at the thirteenth meeting on transcriptional regulation in eukaryotes at CSHL in August 2013.

Summary of the talk:

In yeast, antisense transcription (AST) acts as a “reset” button for gene expression by influencing the chromatin structure at the gene promoter and over the coding region.

The AST-mediated chromatin structures in the coding region of genes facilitates transcription bursting, the major generator of noise in biological systems. This is complemented by the AST-mediated dynamic chromatin structures at the promoter which explain state changes; the capacity to dynamically switch genes from the “off” to the “on” state, also contributing to stochastic expression, and the activation or repression of gene expression.

Alexandre Akoulitchev presents at the 12th annual Northeast ALS Consortium

10/02/2013

Product Development

Старт разработки software для автоматизации технологии

06/02/2007

EpiSwitch™ registered as its trademark

01/01/2009

EpiSwitch™ assay gets approval CE certification

02/01/2009

OBD executes first Development and End-user licence

12/01/2009

in Australia for skin cancer with Clinical Laboratories Pty

Oxford BioDynamics certified ISO 9001:2008 and 13485:2003 compliant

04/01/2010

ISO 13485 (requirements for a comprehensive quality management system for the design and manufacture of medical devices) и ISO 9001(Quality Management System)

EpiSwitch™ robotic platform installed

05/01/2010

OBD is ISO 9001 and ISO 13485 certified for 2012 – 2013

03/04/2012

OBD has been assessed and re-certified for ISO9001 and ISO13485 until 2016

04/01/2013